Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in ...

Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that William Hinshaw, Chief Executive ...

Arcutis Biotherapeutics (NASDAQ:ARQT) rose 12% amid some takeover speculation. The biotech is speculated to have attracted some takeover interest, according to traders, who cited a Betaville "uncooked ...

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

A Philadelphia biotechnology company founded seven years ago by two former Johnson & Johnson executives has a new leader.

NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer.